-
Description
To screen potential inhibitors of Human GAPDH
-
Summary
Glucose 3-Phosphate Dehydrogenase (GAPDH; EC 1.2.1.12) is a cytosolic enzyme, which catalyzes the conversion of Glyceraldehyde 3-Phosphate to 1,3-Bisphosphoglycerate (BPG) with the reduction of NAD to NADH in the glycolytic pathway. GAPDH is a multifunctional protein involved in many intracellular processes such as apoptosis, membrane trafficking, ion metabolism, nuclear translocation etc. Although GAPDH is considered as housekeeping gene, increased GAPDH activity has been detected in various human cancers. Additionally, knockdown of GAPDH has been shown to decrease cell proliferation, cell migration and metastasis in in vitro experiments. Therefore, targeting this key enzyme is essential for developing novel therapeutics for treating cancer. In our GAPDH Inhibitor Screening Kit, Glyceraldehyde 3-Phosphate is oxidized by GAPDH to generate 1,3-Bisphosphoglycerate and NADH, which reduces the probe thereby generating a strong absorbance at 450 nm. In the presence of GAPDH inhibitors, the reactions are impeded, thus decreasing the rate and/or extent of generation of GAPDH-dependent absorbance at OD 450 nm. This kit provides a sensitive, quick, and easy method for screening potential inhibitors of GAPDH. GAPDH Inhibitor Control is included in the kit to compare the efficacy of test inhibitors. The assay is high-throughput adaptable and can be performed in less than 30 min.
-
Detection Method
Absorbance 450 nm
-
Species Reactivity
Human
-
Applications
Screening, characterizing & studying potential inhibitors of Human GAPDH
-
Sample Type
Potential compounds
-
Features Benefits
Simple, sensitive,Quick and easy method for screening potential inhibitors of GAPDH
-
Storage Conditions
-20°C
-
Shipping Conditions
Gel Pack
-
Shelf life
12 months
-
Background
Glucose 3-Phosphate Dehydrogenase (GAPDH; EC 1.2.1.12) is a cytosolic enzyme, which catalyzes the conversion of Glyceraldehyde 3-Phosphate to 1,3-Bisphosphoglycerate (BPG) with the reduction of NAD to NADH in the glycolytic pathway. GAPDH is a multifunctional protein involved in many intracellular processes such as apoptosis, membrane trafficking, ion metabolism, nuclear translocation etc. Although GAPDH is considered as housekeeping gene, increased GAPDH activity has been detected in various human cancers. Additionally, knockdown of GAPDH has been shown to decrease cell proliferation, cell migration and metastasis in in vitro experiments. Therefore, targeting this key enzyme is essential for developing novel therapeutics for treating cancer. In our GAPDH Inhibitor Screening Kit, Glyceraldehyde 3-Phosphate is oxidized by GAPDH to generate 1,3-Bisphosphoglycerate and NADH, which reduces the probe thereby generating a strong absorbance at 450 nm. In the presence of GAPDH inhibitors, the reactions are impeded, thus decreasing the rate and/or extent of generation of GAPDH-dependent absorbance at OD 450 nm. This kit provides a sensitive, quick, and easy method for screening potential inhibitors of GAPDH. GAPDH Inhibitor Control is included in the kit to compare the efficacy of test inhibitors. The assay is high-throughput adaptable and can be performed in less than 30 min.
-
-
Properties
Colorimetric assays or detection use UV absorption or enzymatic color reaction. Human proteins, cDNA and human recombinants are used in human reactive ELISA kits and to produce anti-human mono and polyclonal antibodies. Modern humans (Homo sapiens, primarily ssp. Homo sapiens sapiens). Depending on the epitopes used human ELISA kits can be cross reactive to many other species. Mainly analyzed are human serum, plasma, urine, saliva, human cell culture supernatants and biological samples.
-
Additional description
Tissue, pathway, proteinase, peptidase, protease ,acrosin, lipoprotein, activator, caspase, trypsin, papain, esterase inhibitors are proteins or receptor ligands or receptor antagonists that bind to an enzyme receptor and decreases its activity. Since blocking an enzyme's activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. Not all receptor antagonist that bind to enzymes are inhibitors; enzyme activator ligands or agonists bind to enzymes and increase their enzymatic activity, while enzyme substrates bind and are converted to products in the normal catalytic cycle of the enzyme.
